Orexo/Meda's Edluar gains US approval for insomnia
This article was originally published in Scrip
Executive Summary
The US FDA has approved Orexo's Edluar (sublingual zolpidem) 5mg and 10mg for the treatment of short-term insomnia that is characterised by difficulties with sleep initiation. The product, which was previously known as Sublinox, is expected to be launched in the second half of this year.